Agios continues to advance drug programs in the clinic. For Agios, text mining plays a key role in these advances, providing critical information for decision-making at different stages in the drug discovery process, from bench to bedside.
All pharmaceutical companies need an efficient and compliant system to manage safety data in a responsible way. To accomplish this, Agios is in the process of implementing an Adverse Event Reporting System (AERS). The AERS will support the collection of appropriate data as per FDA/global regulations.
Natural language processing (NLP) is being used in multiple places in the workflow at Agios: to mine AE reports, extract case-data from call center records, and assist with initial coding of reported events and WHO drugs. Agios are using data generated by Linguamatics NLP text mining to help understand the progression of AEs in ongoing clinical trials.
- Identify potential safety issues early - crucial to optimizing investment in R&D and avoiding late stage failures.
- Systematically and accurately capture safety-related events, and potentially enable prospective identification of adverse events and patient trends.
- Dramatically increase the precision and recall of your of literature review results over conventional literature searching.
- Gain actionable insights for key decision‐making from bench to bedside, for drug discovery, development and delivery.
Stuart Murray, PhD, Associate Director, Agios Pharmaceuticals
Stuart Murray is an associate director at Agios Pharmaceuticals. He plays a key role in developing and employing knowledge-driven, integrated data analytics to support ongoing research and clinical programs in the fields of cancer metabolism, metabolic immunology, and rare genetic diseases. Prior to Agios, Stuart spent 14 years in large pharma in Oncology and Systems Biology groups. Stuart received a Ph.D. in biochemistry and genetics from the University of Newcastle-upon-Tyne and did postdoctoral research at Albert Einstein College of Medicine, NY.
Jane Reed, PhD, Head of Life Science Strategy, Linguamatics
Jane Reed is the head of life science strategy at Linguamatics. She is responsible for the life science business unit, developing the strategic vision for Linguamatics’ growing product portfolio, partner relationships and business development for pharma and biotech. Jane has extensive experience in life science informatics. She worked for more than 15 years in vendor companies supplying data products, data integration and analysis and consultancy to pharma and biotech - with roles at Instem, BioWisdom, Incyte, and Hexagen. Before moving into the life science industry, Jane worked in academia with post-docs in genetics and genomics.